Tricyclic Antidepressants Screen

Maybe you take amitriptyline for nerve pain or nortriptyline for migraine, or maybe a urine drug panel came back with a positive you can't explain. Tricyclic antidepressants are an older family of medicines still used for depression and several pain conditions. A positive urine screen can follow a prescribed dose, an overdose, or exposure to another medicine that reacts with the test.

What the Screen Picks Up

This is an established, qualitative urine immunoassay. An immunoassay uses antibodies to recognize drugs or their breakdown products. Qualitative means the result is positive or negative, without an amount. The screen commonly detects amitriptyline, nortriptyline, imipramine, desipramine and doxepin, but its response differs between drugs. It is not designed to detect tetracyclic antidepressants such as maprotiline, which did not react even at high concentrations in assay studies, or newer antidepressants.

Tricyclics take their name from their three-ring chemical structure. Some other medicines have enough chemical similarity to react with the antibodies too. A positive result is therefore preliminary: it does not establish which medicine is present, whether one or several are present, how much you took, or whether it is causing symptoms.

A separate urine confirmation test can identify individual drugs using chromatography with mass spectrometry. These techniques separate compounds and identify them from their chemical signatures. Confirmation covers the drugs included in that analysis. Even a confirmed urine concentration has no established relationship to a safe or toxic dose; blood concentrations and clinical findings serve different purposes.

How Well the Urine Screen Performs

An emergency-department study compared two urine immunoassays with specific drug measurements in serum. Both urine screens produced positives across blood concentrations ranging from below usual treatment levels to toxic levels, so the urine result could not indicate how much drug was in the blood. Neither consistently detected clomipramine, even when its blood concentration was above the treatment range. Cyclobenzaprine caused more false positives with one of the two screens.

A separate study of 44 emergency patients with suspected overdose found that a rapid urine assay missed fewer exposures and produced fewer false positives than an older serum immunoassay. That comparison involved particular assays. It does not establish an accuracy rate for every urine screen or make a negative result sufficient to exclude poisoning.

Heart Rhythm Risk

In an overdose, tricyclics can interfere with the heart's electrical signals by blocking sodium channels in heart muscle. These channels allow electrical activation to spread through the heart. Blocking them can slow conduction, cause dangerous rhythms and lower blood pressure. Severe poisoning can also cause seizures and coma.

An electrocardiogram, or ECG, records the heart's electrical activity. QRS duration describes how long electrical activation takes to spread through its main pumping chambers. In a prospective study of 49 people with acute tricyclic overdose, QRS widening helped predict seizures and dangerous ventricular rhythms, while serum drug levels did not accurately predict those complications.

A separate study of 40 overdose patients found that peak blood concentrations were associated with severe complications and ECG changes. Together, these findings support interpreting drug concentrations with the ECG, symptoms and vital signs. Neither a urine result nor a blood concentration alone can establish the severity of poisoning.

During prescribed use, the evidence about heart attack and sudden cardiac death is less consistent. A study of about 55,000 people linked tricyclic prescriptions to more heart attacks. Another study of about 32,000 people with depression and no previous ischemic heart disease or stroke found an association between predominantly low-dose tricyclic use and major cardiovascular events. A 2024 review found inconsistent differences between individual tricyclics in routine use, despite risk signals for some drugs and outcomes. These studies followed medication use; they did not establish that a positive urine screen predicts future heart problems.

Falls, Fractures and Mortality in Older Adults

Tricyclics can cause drowsiness and a drop in blood pressure when you stand. A 2024 analysis found about 40% higher odds of falls or fractures among older people taking them. The studies differed substantially, and another pooled analysis within that review did not establish a clear increase. These findings describe medication exposure, not the meaning of a positive urine screen.

In a UK cohort of 60,746 older adults with depression, the highest prescribed doses in the category covering tricyclic and related antidepressants were associated with about 43% higher mortality than periods without antidepressant use. The lowest-dose group did not show a statistically clear increase. This category included related medicines as well as tricyclics, and the study used prescription records rather than urine testing.

These observational findings cannot fully separate medication effects from depression, other illnesses and differences between people receiving different treatments. They support attention to medication safety, but a urine positive cannot calculate your fall risk or show that your dose is too high.

Medicines Missing From the Medication List

In a study of 55,296 people receiving care for pain, urine findings sometimes disagreed with the prescriber's medication list. That study used a drug-specific mass spectrometry assay for amitriptyline, nortriptyline and imipramine. It supports using definitive urine testing to investigate uncertain recent use, but its results cannot be treated as the accuracy of this antibody-based screen. A single sample also cannot establish consistent daily adherence.

When Results Can Be Misleading

• Other medicines: cyclobenzaprine and quetiapine can cause false positives on some urine assays; quetiapine's prescribing information warns about this and advises confirmation. Diphenhydramine, cyproheptadine and phenothiazine antipsychotics such as chlorpromazine and thioridazine are also reported causes, especially at high doses or in overdose. The effect depends on the medicine, concentration and assay; taking one of these drugs does not guarantee a false positive.
• Evidence from blood screens: carbamazepine can interfere with some serum tricyclic immunoassays. In a study of 52 children and adolescents, neither carbamazepine nor oxcarbazepine showed significant interference with the urine assay tested. A blood-assay finding should not be assumed to apply to urine.
• Uneven detection: some urine assays detect clomipramine poorly, and one study found misses even at high concentrations in spiked urine. Other drugs can also be missed when the amount in urine is too small for the screen to detect.
• Timing and dilution: a sample taken too soon after a dose, long after the last dose, or after unusually high fluid intake may be negative despite exposure. The result does not identify the exact time or dose taken.
• Differences between assays: urine screens use different antibodies, cutoffs and reference drugs to define a positive. Two assays can disagree on the same specimen, and a positive or negative result should not be treated as a comparable drug concentration across laboratories.

What Repeated Results Mean

Repeated results are separate checks for possible recent exposure. There is no measured level to trend, and a persistent positive does not show that drug exposure is increasing. A switch to negative can reflect timing, dilution or assay sensitivity as well as stopping the medicine.